Kodiak Sciences KOD shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform.
Kodiak Sciences is a clinical stage company. It is engaged in developing innovative therapeutics to treat high prevalence of ophthalmic diseases. The most advanced product candidate of the group is KSI-301, a biologic therapy built with antibody biopolymer conjugate platform, which is designed to maintain potent and effective drug levels in ocular tissue.
Kodiak Sciences shares traded down 4.60% to $156.78 The stock has a 52-week high of $169.98 and a 52-week low of $35.49.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
